Patents by Inventor Thomas Fuchss

Thomas Fuchss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240009175
    Abstract: Substituted tetrazole derivatives are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
    Type: Application
    Filed: March 16, 2021
    Publication date: January 11, 2024
    Applicants: Merck Patent GmbH, RYVU THERAPEUTICS S.A.
    Inventors: Thomas FUCHSS, Lisa Koetzner, Christina Schindler, Daniel Kuhn
  • Publication number: 20230301991
    Abstract: The present invention encompasses ATR inhibitor for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.
    Type: Application
    Filed: October 22, 2021
    Publication date: September 28, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Ulrich BETZ, Thomas FUCHSS
  • Publication number: 20230271956
    Abstract: Substituted amide derivatives are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
    Type: Application
    Filed: March 16, 2021
    Publication date: August 31, 2023
    Applicants: Merck Patent GmbH, RYVU THERAPEUTICS S.A.
    Inventors: Lisa Koetzner, Thomas Fuchss, Christina Schindler, Daniel Kuhn
  • Publication number: 20230226066
    Abstract: The present invention encompasses ATR inhibitor for use in the treatment of virus infections, including SARS-CoV infections such as COVID-19, alone or in combination with one or more additional therapeutic agents.
    Type: Application
    Filed: June 15, 2021
    Publication date: July 20, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Ulrich BETZ, Thomas FUCHSS
  • Publication number: 20230203034
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in Claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: March 1, 2023
    Publication date: June 29, 2023
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Kai SCHIEMANN
  • Publication number: 20230149371
    Abstract: Substituted tetrazole derivatives are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
    Type: Application
    Filed: March 16, 2021
    Publication date: May 18, 2023
    Applicants: Merck Patent GmbH, RYVU THERAPEUTICS S.A.
    Inventors: Thomas FUCHSS, Lisa Koetzner, Christina Schindler, Daniel Kuhn
  • Patent number: 11608338
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: March 21, 2023
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Kai Schiemann
  • Publication number: 20230024721
    Abstract: Compounds of the formula I are inhibitors of HIF-2?, and can be employed for the treatment of diseases such as cancer.
    Type: Application
    Filed: November 24, 2020
    Publication date: January 26, 2023
    Applicants: Merck Patent GmbH, Ryvu Therapeutics S.A.
    Inventors: Matthias LEIENDECKER, Hans-Peter Buchstaller, Thomas Fuchss
  • Publication number: 20220144828
    Abstract: Atropisomers, solid forms, salt forms, and deuterated derivatives of the ATM inhibitor 8-(1,3-Dimethyl-1H-pyrazol-4-yl)-1-(3-fluoro-5-methoxypyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydroimidazo[4,5-c]quinolin-2-one as well as compositions thereof are provided.
    Type: Application
    Filed: March 25, 2020
    Publication date: May 12, 2022
    Applicant: Merck Patent GmbH
    Inventors: Thomas Fuchss, Axel Becker, Holger Kubas, Ulrich Graedler
  • Publication number: 20220117970
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: May 28, 2021
    Publication date: April 21, 2022
    Inventors: Thomas FUCHSS, Ulrich EMDE, Hans-Peter BUCHSTALLER, Werner MEDERSKI
  • Patent number: 11103512
    Abstract: A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: August 31, 2021
    Assignee: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
  • Patent number: 11065253
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: July 20, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Patent number: 11065255
    Abstract: A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 20, 2021
    Assignee: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
  • Patent number: 11053233
    Abstract: An anhydrous disordered crystalline (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be used in pharmaceutical compositions.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 6, 2021
    Assignee: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuníng, Marco Poma, Edoardo Burini
  • Publication number: 20210198257
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 1, 2021
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Kai SCHIEMANN
  • Publication number: 20210113572
    Abstract: A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 22, 2021
    Applicant: Merck Patent GmbH
    Inventors: Michael LANGE, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
  • Patent number: 10975075
    Abstract: The compounds are imidazolonylquinoline compounds of the following formula and are useful in the inhibition, regulation and/or modulation of signal transduction by kinases, in particular ATM kinase, furthermore for the treatment of diseases which relate to ATM kinase, in particular cancer, and which compounds can be supplied in pharmaceutical compositions and kits.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: April 13, 2021
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Kai Schiemann
  • Publication number: 20200325137
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 15, 2020
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Kai SCHIEMANN
  • Patent number: 10745399
    Abstract: A compound of formula (IV) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof These imidazolonylquinoline compounds are useful in the inhibition, regulation and/or modulation of signal transduction by kinases, in particular ATM kinase, furthermore in pharmaceutical compositions, and in their use for the treatment of diseases which relate to ATM kinase, in particular cancer.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 18, 2020
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Kai Schiemann
  • Publication number: 20200123144
    Abstract: An anhydrous disordered crystalline (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be used in pharmaceutical compositions.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 23, 2020
    Applicant: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini